Replies to post #78422 on Biotech Values

[exwannabe]

Re: OT HEB: "Those include all of the failed studies HEB has conducted on Ampligen in any indication. "

Hum, would that not make it about 0.03 trials per indication?

BTW, I mark this as OT because any comment on HEB etc. is really not germane to biotech VALUES.